Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Bylvay® (odevixibat) – New orphan indication
June 13, 2023 - Ipsen announced the FDA approval of Bylvay (odevixibat), for the treatment of cholestatic pruritus in patients 12 months of age and older with Alagille syndrome (ALGS).
